IFNA1 and colorectal carcinoma: We have shown that targeted delivery of IFNα by gene/cell therapy to the liver safely prevents, reduces, or reverts the growth of hepatic CRC metastases improving overall survival of immune‐competent mice, without causing systemic side effects, hematopoietic toxicity, or inability to respond to a virus challenge.